Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 4, 2010, Pages 744-749

  Witt, D M ^a,b   DelatE, T ^a   ClarK, N P ^b   Martell, C ^b   Tran, T ^b   Crowther, M A ^c   Garcia, D A ^d   Ageno, W ^e   Hylek, E M ^f  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF INSUBRIA   (Italy)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical outcomes; International normalized ratio; Monitoring; Warfarin

Indexed keywords

WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; DATA BASE; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOEMBOLISM;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION; CHI-SQUARE DISTRIBUTION; DRUG MONITORING; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; THROMBOEMBOLISM; TIME FACTORS; WARFARIN;

EID: 77952728946     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03756.x     Document Type: Article

References (20)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:160-98.
2. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114:e257-354.
3. Fitzmaurice DA. Oral anticoagulation therapy should be managed in the community with treatment aimed at standard targets and increased recal intervals. J Thromb Haemost 2008, 6:1645-6.
4. Heneghan C, Alonso-Coello P, Garcia-Alamino M, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006, 367:404-11.
5. Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis 1998, 5(Suppl. 1):19-24.
6. Rose AJ, Ozonoff A, Berlowitz DR, Henault LE, Hylek EM. Warfarin dose management affects INR control. J Thromb Haemost 2009, 7:94-101.
7. Guidelines on oral anticoagulation: third edition. Br J Haematol 1998, 101:374-87.
8. Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost 2008, 6:1647-54.
9. Snyder CM, Helms BE, Hall DL. Evaluation of INR monitoring frequency and time in therapeutic range. J Pharm Technol 2008, 24:255-60.
10. Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis 2000, 9:283-92.
11. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005, 127:1515-22.
12. Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, Garcia DA, Ageno W, Hylek EM. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood 2009, 114:952-6.
13. Poller L, Shiach CR, MacCallum PK, Johansen AM, Münster AM, Magalhães A, Jespersen J. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet 1998, 352:1505-9.
14. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care 1995, 33:783-95.
15. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992, 45:197-203.
16. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-45.
17. Yuan S, Ferrell C, Chandler WL. Comparing the prothrombin time INR versus the APTT to evaluate the coagulopathy of acute trauma. Thromb Res 2007, 120:29-37.
18. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996, 335:540-6.
19. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003, 349:1019-26.
20. Clark NP, Witt DM, Delate T, Trapp M, Garcia D, Ageno W, Hylek EM, Crowther MA. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study. Pharmacotherapy 2008, 28:960-7.